Acumen Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-32.7M | $-20.7M | $-25.1M | $-26.5M | $-41.0M | $-28.8M | $-37.2M | $-29.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $11.0K | $12.0K | $12.0K | $15.0K | $16.0K | $15.0K | $14.0K | $16.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.5M | $2.4M | $2.4M | $2.5M | $2.5M | $2.5M | $2.3M | $2.3M |
| Net Cash from Operating Activities | $-18.1M | $-24.1M | $-19.1M | $-30.5M | $-31.8M | $-34.1M | $-27.2M | $-24.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $9.0K | $79.0K | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $26.0M | $-13.8M | $26.3M | $40.5M | $38.5M | $28.7M | $29.7M | $-10.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-278.0K | $35.7M | $2.0K | $0 | $0 | $-36.0K | $-9.0K | $-42.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-18.1M | $-24.1M | $-19.1M | $-30.5M | $-31.8M | $-34.2M | $-27.2M | $-24.6M |